Score Overview
Explore the 2021 public Archive ranking →
Where Vertex Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. VRTX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 527.67 | — |
1 Year2025-09-26 | $ 385.74 | 36.79% |
5 Years2021-09-28 | $ 181.60 | 190.57% |
10 Years2016-09-28 | $ 88.84 | 493.96% |
20 Years2006-09-28 | $ 33.39 | 15x |
30 Years1996-09-27 | $ 14.63 | 36x |
All Time1991-07-24 | $ 4.50 | 117x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1991-07-24 |
|---|---|---|---|---|---|---|---|
| Price | $ 527.67 | $ 385.74 | $ 181.60 | $ 88.84 | $ 33.39 | $ 14.63 | $ 4.50 |
| Return | — | 36.79% | 190.57% | 493.96% | 15x | 36x | 117x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 12.62B | $ 4.40B | $ 7.85B |
| 2025 | $ 12.07B | $ 3.95B | $ 6.61B |
| 2024 | $ 11.02B | -$ 535M | $ 6.11B |
| 2023 | $ 9.86B | $ 3.61B | $ 11.21B |
| 2022 | $ 8.93B | $ 3.32B | $ 10.77B |
| 2021 | $ 7.57B | $ 2.34B | $ 7.52B |
| 2020 | $ 6.20B | $ 2.71B | $ 6.65B |
| 2019 | $ 4.16B | $ 1.17B | $ 3.80B |
| 2018 | $ 3.04B | $ 2.09B | $ 3.16B |
| 2017 | $ 2.48B | $ 263M | $ 2.08B |
| 2016 | $ 1.70B | -$ 112M | $ 1.43B |
| 2015 | $ 1.03B | -$ 558M | $ 1.04B |
| 2014 | $ 580M | -$ 738M | $ 1.38B |
| 2013 | $ 1.21B | -$ 445M | $ 1.46B |
| 2012 | $ 1.52B | -$ 107M | $ 1.32B |
| 2011 | $ 1.41B | $ 29M | $ 968M |
| 2010 | $ 143M | -$ 754M | $ 1.03B |
| 2009 | $ 102M | -$ 641M | $ 1.28B |
| 2008 | $ 175M | -$ 459M | $ 832M |
| 2007 | $ 199M | -$ 391M | $ 460M |
| 2006 | $ 216M | -$ 206M | $ 704M |
| 2005 | $ 160M | -$ 203M | $ 361M |
| 2004 | $ 102M | -$ 166M | $ 386M |
| 2003 | $ 69M | -$ 196M | $ 583M |
| 2002 | $ 161M | -$ 108M | $ 634M |
| 2001 | $ 167M | -$ 66M | $ 743M |
| 2000 | $ 78M | -$ 39M | $ 459M |
| 1999 | $ 61M | -$ 41M | $ 187M |
| 1998 | $ 44M | -$ 33M | $ 24M |
| 1997 | $ 43M | -$ 19M | $ 71M |
| 1996 | $ 13M | -$ 40M | $ 34M |
| 1995 | $ 22M | -$ 21M | $ 28M |
| 1994 | $ 19M | -$ 17M | $ 71M |
| 1993 | $ 27M | $ 2M | $ 28M |
| 1992 | $ 3M | -$ 8M | $ 11M |
| IPO1991 | $ 3M | -$ 5M | $ 27M |
Vertex Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 6.20B to $ 12.07B and net income grew from $ 2.71B to $ 3.95B. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 1.03B to $ 12.07B and net income went from -$ 558M to $ 3.95B. Revenue increased in every one of those 10 years; net income in 7.
Vertex Pharmaceuticals Inc currently holds a 20-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.
Membership
Explore VRTX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
